Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547563 | 0.85 | MDM2 (0.49) | SIGMAR1TP53MDM2HSD17B2MEN1 | |
| SCHEMBL15744018 | 0.79 | HSD17B2 (0.42) | SIGMAR1MDM2HSD17B2 | |
| SCHEMBL13413307 | 0.77 | SIGMAR1 (0.32) | SIGMAR1HSD17B2 | |
| SCHEMBL13395242 | 0.75 | SIGMAR1 (0.31) | SIGMAR1HSD17B2 | |
| SCHEMBL13547532 | 0.75 | MDM2 (0.40) | SIGMAR1TP53MDM2HSD17B2P2RX7 | |
| SCHEMBL13413104 | 0.69 | FADS1 (0.38) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL14214482 | 0.69 | FADS1 (0.38) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL14214495 | 0.69 | FADS1 (0.38) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL14214701 | 0.68 | SIGMAR1 (0.43) | SIGMAR1 | |
| SCHEMBL3370155 | 0.68 | PER2 (0.38) | SIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | SIGMAR1 1721/4885TP53 3947/4885MDM2 4261/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | SIGMAR1 1721/4885TP53 3947/4885MDM2 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.